Japanese pharmaceutical firm Takeda intends to establish a subsidiary inthe UK as part of its plans to expand it global operations. The company already has subsidiaries in Germany, France and Italy, as well as the Takeda Europe R&D Center, which has offices in Frankfurt and London.
Takeda currently has two products available in the UK; Zoton (lansoprazole), a gastrointestinal agent, and Prostap SR (leuprorelin acetate), an anticancer therapy, both of which are available through the firm's licensee, Wyeth Laboratories. Takeda says it will bring a pipeline of new products to the UK, led by its angiotensin II antagonist, candesartan celexetil, for the treatment of hypertension.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze